Abstract
Pediatric patients are among the primary patient groups where positron emission tomography/magnetic resonance imaging (PET/MRI) is considered to have significant advantages, due to its ability to reduce radiation dose by up to 70-80%, high soft tissue resolution, and to obtain diagnostic MRI and PET images in a single anesthesia session. Due to the fact that pediatric patients are more sensitive to radiation compared to adults and are exposed to repeated imaging during follow-up, reducing the cumulative radiation dose in these patients through PET/MRI imaging is of great importance. Studies on hybrid PET/MRI in pediatric oncology patients have shown that, in addition to reducing radiation dose, PET/MRI provides diagnostic performance in lesion detection that is at least as good as PET/computed tomography, owing to its high soft tissue resolution. Therefore, when available, PET/MR is supported as the primary PET imaging modality in pediatric oncology. The aim of this review is to present the role of hybrid PET/MR imaging in pediatric oncology diseases in light of the literature.
Keywords: Positron emission tomography/magnetic resonance imaging, hybrid imaging, pediatric tumors
References
Giraudo C, Carraro S, Zucchetta P, Cecchin D. Pediatric imaging using PET/MR imaging. Magn Reson Imaging Clin N Am. 2023;31:625-636.
Kwatra NS, Lim R, Gee MS, States LJ, Vossough A, Lee EY. PET/MR imaging: current updates on pediatric applications. Magn Reson Imaging Clin N Am. 2019;27:387-407.
Chawla SC, Federman N, Zhang D, et al. Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol. 2010;40:681-686.
Martin O, Schaarschmidt BM, Kirchner J, et al. PET/MRI versus PET/CT for whole-body staging: results from a single-center observational study on 1,003 sequential examinations. J Nucl Med. 2020;61:1131-1136.
Zucchetta P, Branchini M, Zorz A, et al. Quantitative analysis of image metrics for reduced and standard dose pediatric 18F-FDG PET/MRI examinations. Br J Radiol. 2019;92:20180438.
Aydos U, Balcı E, Ateş SG, Akdemir ÜÖ, Karadeniz C, Atay LÖ. Quantitative and visual analyses of the effect of activity reduction on image metrics and quality in 18F-FDG PET/MRI in pediatric oncology. Turk J Med Sci. 2023;53:289-302.
Schäfer JF, Gatidis S, Schmidt H, et al. Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology. 2014;273:220-231.
Uslu-Beşli L, Atay Kapucu L, Karadeniz C, et al. Comparison of FDG PET/MRI and FDG PET/CT in pediatric oncology in terms of anatomic correlation of FDG-positive lesions. J Pediatr Hematol Oncol. 2019;41:542-550.
Baratto L, Hawk KE, States L, et al. PET/MRI improves management of children with cancer. J Nucl Med. 2021;62:1334-1340.
States LJ, Reid JR. Whole-Body PET/MRI Applications in pediatric oncology. AJR Am J Roentgenol. 2020;215:713-725.
Catana C. Motion correction options in PET/MRI. Semin Nucl Med. 2015;45:212-223.
Cecchin D, Barthel H, Poggiali D, et al. A new integrated dual time-point amyloid PET/MRI data analysis method. Eur J Nucl Med Mol Imaging. 2017;44:2060-2072.
Rauscher I, Eiber M, Fürst S, et al. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. J Nucl Med. 2014;55:724-729.
Wang X, Cui Y, Wang Y, et al. Assessment of lung nodule detection and lung CT screening reporting and data system classification using zero echo time pulmonary MRI. J Magn Reson Imaging. 2024 Apr 11.
Gatidis S, Schmidt H, Gücke B, et al. Comprehensive Oncologic imaging in infants and preschool children with substantially reduced radiation exposure using combined simultaneousF-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging: a direct comparison to F-fluorodeoxyglucose positron emission tomography/computed tomography. Invest Radiol. 2016;51:7-14.
Hirsch FW, Sattler B, Sorge I, et al. PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol. 2013;43:860-875.
Ponisio MR, McConathy J, Laforest R, Khanna G. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatr Radiol. 2016;46:1258-1268.
Sher AC, Seghers V, Paldino MJ, et al. Assessment of sequential PET/MRI in comparison with PET/CT of pediatric lymphoma: a prospective study. AJR Am J Roentgenol. 2016;206:623-631.
Spijkers S, Littooij AS, Nievelstein RAJ. Measurements of cervical lymph nodes in children on computed tomography. Pediatr Radiol. 2020;50:534-542.
Muehe AM, Siedek F, Theruvath AJ, et al. Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. Theranostics. 2020;10:3612-3621.
Gawande RS, Khurana A, Messing S, et al. Differentiation of normal thymus from anterior mediastinal lymphoma and lymphoma recurrence at pediatric PET/CT. Radiology. 2012;262:613-622.
Person A, Janitz E, Thapa M. Pediatric bone marrow: normal and abnormal MRI appearance. Semin Roentgenol. 2021;56:325-337.
Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol. 2001;177:229-236.
Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007;37:316-331.
Panigrahy A, Blüml S. Neuroimaging of pediatric brain tumors: from basic to advanced magnetic resonance imaging (MRI). J Child Neurol. 2009;24:1343-1365.
Pedersen C, Aboian M, McConathy JE, Daldrup-Link H, Franceschi AM. PET/MRI in pediatric neuroimaging: primer for clinical practice. AJNR Am J Neuroradiol. 2022;43:938-943.
Harat M, Rakowska J, Harat M, et al. Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma. Nat Commun. 2023;14:4572.
Hojjati M, Badve C, Garg V, et al. Role of FDG-PET/MRI, FDG-PET/CT, and dynamic susceptibility contrast perfusion mri in differentiating radiation necrosis from tumor recurrence in glioblastomas. J Neuroimaging. 2018;28:118-125.
Pyatigorskaya N, Sgard B, Bertaux M, Yahia-Cherif L, Kas A. Can FDG-PET/MR help to overcome limitations of sequential MRI and PET-FDG for differential diagnosis between recurrence/progression and radionecrosis of high-grade gliomas? J Neuroradiol. 2021;48:189-194.
Pyka T, Hiob D, Preibisch C, et al. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. Eur J Radiol. 2018;103:32-37.
Marner L, Lundemann M, Sehested A, et al. Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors. Neuro Oncol. 2021;23:2107-2116.
Marner L, Nysom K, Sehested A, et al. Early Postoperative 18F-FET PET/MRI for pediatric brain and spinal cord tumors. J Nucl Med. 2019;60:1053-1058.
Preuss M, Werner P, Barthel H, et al. Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. Childs Nerv Syst. 2014;30:1399-1403.
Shankar A, Bomanji J, Hyare H. Hybrid PET-MRI imaging in paediatric and TYA brain tumours: clinical applications and challenges. J Pers Med. 2020;10:218.
Tsouana E, Stoneham S, Fersht N, et al. Evaluation of treatment response using integrated 18F-labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours. Pediatr Blood Cancer. 2015;62:1661-1663.
Chun GYC, Sample J, Hubbard AK, Spector LG, Williams LA. Trends in pediatric lymphoma incidence by global region, age and sex from 1988-2012. Cancer Epidemiol. 2021;73:101965.
Pfister SM, Reyes-Múgica M, zar AJ, et al. Summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era. Cancer Discov. 2022;12:331-355.
Kirchner J, Deuschl C, Schweiger B, et al. Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI. Eur J Nucl Med Mol Imaging. 2017;44:1742-1750.
Jannusch K, Morawitz J, Schweiger B, et al. [18F]FDG PET/MRI in children suffering from lymphoma: does MRI contrast media make a difference? Eur Radiol. 2023;33:8366-8375.
Giraudo C, Raderer M, Karanikas G, et al. 18F-Fluorodeoxyglucose positron emission tomography/magnetic resonance in lymphoma: comparison with 18F-fluorodeoxyglucose positron emission tomography/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging. Invest Radiol. 2016;51:163-169.
Verhagen MV, Menezes LJ, Neriman D, et al. 18F-FDG PET/MRI for Staging and interim response assessment in pediatric and adolescent hodgkin lymphoma: a prospective study with 18F-FDG PET/CT as the reference standard. J Nucl Med. 2021;62:1524-1530.
Rashidi A, Baratto L, Theruvath AJ, et al. Diagnostic accuracy of 2-[18F]FDG-PET and whole-body DW-MRI for the detection of bone marrow metastases in children and young adults. Eur Radiol. 2022;32:4967-4979.
Dahlsgaard-Wallenius SE, Hildebrandt MG, et al. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review. Eur J Nucl Med Mol Imaging. 2021;48:584-91.
Morakote W, Baratto L, Ramasamy SK, et al. Comparison of diffusion-weighted MRI and [18F]FDG PET/MRI for treatment monitoring in pediatric Hodgkin and non-Hodgkin lymphoma. Eur Radiol. 2024;34:643-653.
Arndt CA, Rose PS, Folpe AL, Laack NN, editors. Common musculoskeletal tumors of childhood and adolescence. Mayo Clinic Proceedings; 2012: Elsevier.
Guja KE, Behr G, Bedmutha A, Kuhn M, Nadel HR, Pandit-Taskar N. Molecular imaging with PET-CT and PET-MRI in pediatric musculoskeletal diseases. Semin Nucl Med. 2024;54:438-455.
Ricard F, Cimarelli S, Deshayes E, Mognetti T, Thiesse P, Giammarile F. Additional benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med. 2011;36:672-627.
van Ewijk R, Schoot RA, Sparber-Sauer M, et al. European guideline for imaging in paediatric and adolescent rhabdomyosarcoma - joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology. Pediatr Radiol. 2021;51:1940-1951.
Pourmehdi Lahiji A, Jackson T, Nejadnik H, et al. Association of tumor [18F]FDG activity and diffusion restriction with clinical outcomes of rhabdomyosarcomas. Mol Imaging Biol. 2019;21:591-598.
Zhang X, Chen YL, Lim R, Huang C, Chebib IA, El Fakhri G. Synergistic role of simultaneous PET/MRI-MRS in soft tissue sarcoma metabolism imaging. Magn Reson Imaging. 2016;34:276-279.
Padwal J, Baratto L, Chakraborty A, et al. PET/MR of pediatric bone tumors: what the radiologist needs to know. Skeletal Radiol. 2023;52:315-328.
Eiber M, Takei T, Souvatzoglou M, et al. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med. 2014;55:191-197.
Chodyla M, Barbato F, Dirksen U, et al. Utility of Integrated PET/MRI for the primary diagnostic work-up of patients with ewing sarcoma: preliminary results. Diagnostics (Basel). 2022;12:2278.
Giraudo C, Fichera G, Stramare R, et al. Radiomic features as biomarkers of soft tissue paediatric sarcomas: preliminary results of a PET/MR study. Radiol Oncol. 2022;56:138-141.
Orsatti G, Zucchetta P, Varotto A, et al. Volumetric histograms-based analysis of apparent diffusion coefficients and standard uptake values for the assessment of pediatric sarcoma at staging: preliminary results of a PET/MRI study. Radiol Med. 2021;126:878-885.
Maennlin S, Chaika M, Gassenmaier S, et al. Evaluation of functional and metabolic tumor volume using voxel-wise analysis in childhood rhabdomyosarcoma. Pediatr Radiol. 2023;53:438-449.
Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556-2562.
Binkovitz LA, Olshefski RS, Adler BH. Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings. Pediatr Radiol. 2003;33:598-602.
Ferrell J, Sharp S, Kumar A, Jordan M, Picarsic J, Nelson A. Discrepancies between F-18-FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2021;68:e28891.
Sher AC, Orth R, McClain K, Allen C, Hayatghaibi S, Seghers V. PET/MR in the assessment of pediatric histiocytoses: a comparison to PET/CT. Clin Nucl Med. 2017;42:582-588.
Wang F, Xu Y. The diagnostic value of 18F-FDG PET/MR in Langerhans histiocytosis in children. J Nuc Med. 2022;63:3129.
Baratto L, Nyalakonda R, Theruvath AJ, et al. Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging. 2023;50:1689-1698.
Colon NC, Chung DH. Neuroblastoma. Adv Pediatr. 2011;58:297-311.
Vik TA, Pfluger T, Kadota R, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784-790.
Papathanasiou ND, Gaze MN, Sullivan K, et al. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med. 2011;52:519-525.
Liu J, Li C, Yang X, et al. The diagnostic value of 18F-FDG PET/CT bone marrow uptake pattern in detecting bone marrow involvement in pediatric neuroblastoma patients. Contrast Media Mol Imaging. 2022 Jan 6;2022:7556315.
Bar-Sever Z, Keidar Z, Ben-Barak A, et al. The incremental value of 18F-FDG PET/CT in paediatric malignancies. Eur J Nucl Med Mol Imaging. 2007;34:630-637.
Soliman H, El-Noueam K, Ettaby A, Fadel S, Abougabal AM. Whole-body three-dimensional short tau inversion recovery and T1-weighted in/opposed phase MRI in the detection of neuroblastoma bone marrow metastasis: comparative study with PET/CT utilising bone marrow biopsy as the reference standard. Clin Radiol. 2023;78:e535-e541.
Kong G, Hofman MS, Murray WK, et al. Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol. 2016;38:87-96.
Kroiss A, Putzer D, Uprimny C, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865-873.
Combemale P, Valeyrie-Allanore L, Giammarile F, et al. Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. PLoS One. 2014;9:e85954.
Reinert CP, Schuhmann MU, Bender B, et al. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging. 2019;46:776-787.
Voss SD. Functional and anatomical imaging in pediatric oncology: which is best for which tumors. Pediatr Radiol. 2019;49:1534-1544.
Evans DGR, Salvador H, Chang VY, et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res. 2017;23:e46-e53.
Raad RA, Lala S, Allen JC, et al. Comparison of hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1. World J Nucl Med. 2018;17:241-248.
